Transcode Therapeutics, Inc.

RNAZ Nasdaq CIK: 0001829635

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation DE
Business Address 6 LIBERTY SQUARE, BOSTON, MA, 02109
Mailing Address 6 LIBERTY SQUARE, BOSTON, MA, 02109
Phone 857-301-6857
Fiscal Year End 1231
EIN 811065054

Recent SEC Filings

Form Type Date Filed Document
10-K Annual financial report April 15, 2026 View on SEC
8-K Current report of material events April 7, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC
8-K Current report of material events February 23, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 7, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
8-K/A Current report amendment December 23, 2025 View on SEC
8-K Current report of material events December 22, 2025 View on SEC
3 Initial insider ownership report December 22, 2025 View on SEC

Annual Reports

10-K April 15, 2026
  • Advancing lead drug candidate TTX-MC138 through Phase 0/1 clinical trials for solid tumors.
  • Strategic acquisition of ABCJ, LLC (Polynoma) expanded pipeline into immunotherapy with BRACO-19.
View Analysis

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.